Brief summary

The study is designed to evaluate the safety and effectiveness of the

Transcatheter Aortic Valve and Recapturable Delivery System (product

of Shanghai MicroPort CardioFlow Medtech Co., Ltd.)

It is a prospective, multicenter, single arm, objective performance

criteria controlled clinical investigation

Primary endpoint

Cumulative all cause mortality of 12 months

CERC Services

Core Lab activities

Countries

China

 Number of patients

144

Centers number

18